FDA approves at-home starter dose of Eisai-Biogen Alzheimer's drug
Merck-Eisai's combination cancer therapy fails to meet main goals of late-stage study
These Alzheimer's drugs were supposed to revolutionize the way we fight the disease. The reality is more complicated.
Merck, Eisai discontinue late-stage study for liver cancer therapy
Merck-Eisai's cancer drug combo meets one main goal in late-stage study
US FDA approves injectable version of Eisai-Biogen's Alzheimer's drug
Patients still benefit from Eisai and Biogen Alzheimer's drug after four years, study finds
EU authorizes Eisai-Biogen's drug for treatment of early Alzheimer's disease
EU regulator not updating opinion on Eisai-Biogen's Alzheimer's drug
Europe to review safety data for Eisai-Biogen Alzheimer's drug
US FDA OKs monthly maintenance dosing for Eisai/Biogen's Alzheimer's drug
Merck and Eisai's cancer drugs fail to improve overall survival in late-stage trial
EU drugs regulator recommends Alzheimer's drug from Eisai-Biogen